An open label, phase Ib, dose-escalation study evaluatin

Project: Research project

Project Details

Description

An open label, phase Ib, dose-escalation study evaluating the safety & tolerability of BI 836845 andabemaciclib in patients with locally advanced or
StatusActive
Effective start/end date1/1/171/30/22

Funding

  • Boehringer-Ingelheim Pharmaceuticals

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.